

Resource Summary Report

Generated by [RRID](#) on Aug 25, 2026

NG-ABE8e

RRID:Addgene_138491

Type: Plasmid

Proper Citation

RRID:Addgene_138491

Plasmid Information

URL: <http://www.addgene.org/138491>

Proper Citation: RRID:Addgene_138491

Insert Name: ecTadA(8e)-nSpCas9 (NG)

Organism: Other

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:32433547](#)

Vector Backbone Description: Vector Backbone:pCMV with a BR322 origin; Vector Types:Mammalian Expression; Bacterial Resistance:Ampicillin

Plasmid Name: NG-ABE8e

Record Creation Time: 20220422T221801+0000

Record Last Update: 20260815T080623+0000

Ratings and Alerts

No rating or validation information has been found for NG-ABE8e.

No alerts have been found for NG-ABE8e.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Hu SW, et al. (2025) PAM-flexible adenine base editing rescues hearing loss in a humanized MPZL2 mouse model harboring an East Asian founder mutation. *Nature communications*, 16(1), 7186.

Rose I, et al. (2025) Correction: Adenine base editing of CFTR using receptor targeted nanoparticles restores function to G542X cystic fibrosis airway epithelial cells. *Cellular and molecular life sciences : CMLS*, 82(1), 341.

Chen C, et al. (2025) Massively parallel variant-to-function mapping determines functional regulatory variants of non-small cell lung cancer. *Nature communications*, 16(1), 1391.

Tachida Y, et al. (2025) Systematic empirical evaluation of individual base editing targets: Validating therapeutic targets in USH2A and comparison of methods. *Molecular therapy : the journal of the American Society of Gene Therapy*, 33(4), 1466.

Croce KR, et al. (2025) A rare genetic variant confers resistance to neurodegeneration across multiple neurological disorders by augmenting selective autophagy. *Neuron*.

Valdez I, et al. (2025) A streamlined base editor engineering strategy to reduce bystander editing. *Nature communications*, 16(1), 8115.

Kleinboehl EW, et al. (2024) Development and testing of a versatile genome editing application reporter (V-GEAR) system. *Molecular therapy. Methods & clinical development*, 32(2), 101253.

An M, et al. (2024) Systematic identification of pathogenic variants of non-small cell lung cancer in the promoters of DNA-damage repair genes. *EBioMedicine*, 110, 105480.

Liu Y, et al. (2024) Genetically modified pigs with CD163 point mutation are resistant to HP-PRRSV infection. *Zoological research*, 45(4), 833.

Fernandez MM, et al. (2024) Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis. *Cancer research communications*, 4(9), 2498.

Asante Y, et al. (2023) PAX3-FOXO1 uses its activation domain to recruit CBP/P300 and shape RNA Pol2 cluster distribution. *Nature communications*, 14(1), 8361.

Chai AC, et al. (2023) Single-swap editing for the correction of common Duchenne muscular dystrophy mutations. *Molecular therapy. Nucleic acids*, 32, 522.

Jing Q, et al. (2023) Highly Efficient A-to-G Editing in PFFs via Multiple ABEs. *Genes*, 14(4).

Su J, et al. (2023) In vivo adenine base editing corrects newborn murine model of Hurler syndrome. *Molecular biomedicine*, 4(1), 6.

Schuster SL, et al. (2023) Multi-level functional genomics reveals molecular and cellular oncogenicity of patient-based 3' untranslated region mutations. *Cell reports*, 42(8),

112840.

McAuley GE, et al. (2023) Human T cell generation is restored in CD3[?] severe combined immunodeficiency through adenine base editing. *Cell*, 186(7), 1398.

Nishiyama T, et al. (2022) Precise genomic editing of pathogenic mutations in RBM20 rescues dilated cardiomyopathy. *Science translational medicine*, 14(672), eade1633.

Sayed S, et al. (2022) Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing. *Cancer research*, 82(17), 3002.

Tu T, et al. (2022) A precise and efficient adenine base editor. *Molecular therapy : the journal of the American Society of Gene Therapy*, 30(9), 2933.

Sidorova OA, et al. (2022) RNAi-Mediated Screen of Primary AML Cells Nominates MDM4 as a Therapeutic Target in NK-AML with DNMT3A Mutations. *Cells*, 11(5).